Oncolytics Biotech®Partner Adlai Nortye Doses First Patient in Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer
- Thursday, October 14, 2021, 7:05
- Finance
- Add a comment
Trial is designed to advance pelareorep’s clinical development in China, the world’s second-largest pharmaceutical market SAN DIEGO and CALGARY, AB, Oct. 14, 2021 /PRNewswire/ — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that its partner Adlai Nortye has initiated…
About the Author
adminasapcorp has written 41611 stories on this site.